🚀 #ACC27-#WCCardio Early Bird Registration Now Open!

The global CV community is coming together in Houston for breakthrough science, practical education and worldwide collaboration.

📍 Houston | April 10-12, 2027

Register by Dec. 2 to save ➡️ bit.ly/3N7hU5j #CardioX

🚨 Deadline Approaching!

Showcase your cardiovascular knowledge with ACC’s #CCKE. Created specifically for NPs & PAs, the CCKE features 150 multiple-choice questions that assess knowledge across the full spectrum of #CVD.

⏰ Applications due: Nov. 6 ➡️ bit.ly/3Llin2N

📢 【TCT 2026開催中！】🫀🔥🇺🇸
🎁なんと JACC同時掲載論文が発表後24時間限定で無料公開！FREE ACCESS！今ならゲット！ 👀📖

サンディエゴで開催中のTCT 2026（10/31–11/3）。世界中のインターベンション医が集結し、JACCファミリーからも注目研究が続々と同時掲載！

🇯🇵 PREMIUM Trial — y PCI時のアスピリン省略と出血高リスク患者の解析！

🪨 NODULE-SHOCK — 石灰化結節にRotablation＋IVLはIVL単独を上回る？

⚡ TECTONIC CAD — 高度石灰化冠動脈病変に対するIVLのPivotal Study！

🫀 ANDES Trial — LAA閉鎖後の短期抗凝固療法 vs DAPT、1年成績は？

🔧 EXPLORE MR — 二次性MRに対する後尖修復の可能性！

🔒 PARADIGM — 弁周囲逆流に対する専用経カテーテル閉鎖デバイスの30日成績！

💓 次世代LAA Occluder — Dual-Sealデバイスの1年安全性・有効性！

👉 冠動脈からStructural Heartまで、注目研究を無料で読めるこの機会をお見逃しなく！ 🔥

🔗 jacc.org/events/confere…

@MitsuakiSawano @Nobu0129 @KenEjiri @SS_cardiol @SK2798 @foreverhero0819 @ACCinTouch @JACCJournals @m3com_editors @TCTMD

#TCT2026 #JACC #JACCInterventions #PCI #StructuralHeart #JACCばらん

What were the biggest takeaways from Day 3️⃣ of #TCT2026?

Drs. @rallamee, John A. Spertus and Sanket Dhruva share their perspectives on the latest clinical trial findings, including PROGRESS and CLASP II TR.

📹 Watch the full video 👉 bit.ly/4z198YO #CardioX

Angiography-derived vFFR-guided revascularization met the prespecified absolute criterion for noninferiority to wire-based FFR, according to results from the LIPSIA-STRATEGY trial presented at #TCT2026 and simultaneously published in #JACC. 🔗 bit.ly/4szDdNj

@crfheart

SIRONA: Through 3 years, no between-group differences were observed in walking capacity and health-related quality of life or clinical safety outcomes between SCB angioplasty and the PCB strategy.

Get full details: 🔗 bit.ly/4BA3VcN

#TCT2026 #JACCINT #CardioX @crfheart

Check out #JACCGlobalBurdenCVD Hub for the latest findings and resources to assist with targeted efforts to decrease the burden of CVDs in regions around the world. 🔗 bit.ly/4pxeDe6

#TCT2026

📹 Hear from Jennifer Rymer, MD, FACC, member of #ACCEarlyCareer Membership Section Leadership Council, as she highlights LBCS from Day 3️⃣ of #TCT2026 and shares key insights from 👇

✅ AIR STEMI
✅ TomorrowLAND
✅ SIRONA

Learn more about the trials ➡️ bit.ly/4iuTCy6

There’s lots of buzz around PROGRESS at #TCT2026! 🐝

📹 #ACCPresident @Drroxmehran shares insights on the trial, the critical role of the Heart Team and the value of real-world data from the #TVTRegistry.

🔗 bit.ly/4iuTCy6 #CardioX

TomorrowLAND: Prolonged perfusion balloon predilation & intracoronary delivery of Nicorandil with the Rx Ryusei perfusion balloon did not significantly reduce slow-flow or no-reflow in patients presenting with #STEMI undergoing primary #PCI.

↪️ bit.ly/4zZPblO

#TCT2026

Angiography-derived vFFR-guided revascularization met the prespecified absolute criterion for noninferiority to wire-based FFR, according to results from the LIPSIA-STRATEGY trial presented at #TCT2026 and simultaneously published in #JACC. 🔗 bit.ly/4sX1sFH

@crfheart

SIRONA: Through 3 years, no between-group differences were observed in walking capacity and health-related quality of life or clinical safety outcomes between SCB angioplasty and the PCB strategy. 🔗 bit.ly/4ivIMaV

#JACCINT #TCT2026 #CardioX @crfheart

#GBDStudy: Women account for more deaths from degenerative mitral valve disease (DMVD), while age-standardized mortality is rising in low SDI regions & the total number of people w/ DMVD has more than doubled since 1990. bit.ly/4sMRcj1

#TCT2026 #CardioX @JACCJournals

CLASP II TR: Among patients w/ symptomatic severe #vhdTR, TTVr w/ the PASCAL system in addition to OMT showed significant ↗️ in health status at one year when compared to OMT alone & no significant difference in mortality or HF hospitalization. bit.ly/4ks4qPZ

#TCT2026

Reduced-dose #NOACs as well as aspirin alone were noninferior to #DAPT for a composite of adverse clinical outcomes through six months following LAAC, according to results from the SIMPLAAFY trial presented at #TCT2026.

Read more: bit.ly/4AdRF0h #CardioX

PROGRESS: In patients w/ moderate aortic stenosis & at least one at-risk feature, earlier #TAVR lowered the incidence of death or HF event, reduced HF hospitalizations & improved quality of life at two years compared to clinical surveillance. 🔗 bit.ly/4jOVowj

#TCT2026

💡 Looking for new ways to get involved with ACC?

Stop by the ACC booth #3051 at #TCT2026 and learn how ACC’s Interventional Member Section can help you connect, contribute, and engage with colleagues who share your interests. 🔗 bit.ly/3WJyJYC

#ACCIC

Hear from Drs. @rallamee, John A. Spertus, & John Bittl as they discuss the highlights from Day 2️⃣ of #TCT2026 & preview what's ahead on Day 3️⃣, including the simultaneous publication of LBCTs in #JACC!

Stay tuned for more insights 👉 bit.ly/4A4utBk @crfheart #CardioX

📍 Stop by the ACC booth #3051 at #TCT2026 to save on your ACC membership!

ICYMI: 🔑 Key findings from #TCT2026 LBCTs

P4: A CCTA-guided #PCI strategy was noninferior to IVUS–guided PCI for target-vessel failure at 12 months.

TRANSFORM II: Sirolimus-coated balloon was noninferior to EES in native coronary arteries.

🔗 bit.ly/3W5NViJ #CardioX

🆕 late-breaking research presented at #TCT2026 highlights the cost-effectiveness of early #TAVR in asymptomatic severe #vhdAS, the association between increasing #vhdTR severity & mortality, & the benefits of transcatheter tricuspid valve repair. 👇 bit.ly/4sDO6Og